Radar›Companies›Top Biological Products, Excluding Disgnostic Substances Stocks in USA
United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Top Biological Products, Excluding Disgnostic Substances Stocks in USA

Five U.S.-listed biological products, excluding disgnostic substances names, read through one evidence stack: market path, official filing history, profitability, readiness, Prism attention and industry context.

Snapshot: 13 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderGilead · 65
Strongest available pathExelixis · +164.0%
Widest latest marginExelixis · 33.7%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1GILD · Nasdaq

Gilead

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2015Palo Alto, California$171.29B market cap
View full Companies Radar profile
65Solid
Snapshot price$138.1as of page date
Monthly-close return+89.8%five-year window
FY2025 revenue$29.44BGILEAD SCIENCES, INC.
Net margin28.9%FY2025
P/E snapshot14.0xone ratio, not a verdict
Prism attention34.3%share across these five
Filing track recordRevenue, USD billions
+7.8%
$0$9.8B$19.6B$29.4BFY2021: $27.305BFY2022: $27.281BFY2023: $27.116BFY2024: $28.754BFY2025: $29.443B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.9%
52-week position61% through range
$108.5$157.3
News mentions41.6K
Community mentions8.1Kpartial coverage
U.S.-scope patents13744
Prism Insights

What sits behind the readiness signal

Observed risk 8/100higher means more observed risk
Earnings signal77/100
Management stability90/100
Market position52/100
Capital-event signal90/100
Innovation pulse22/100
Management signal

No leadership-churn flag in the model; 6 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 96 M&A involvements, 13 asset-acquisition events and 40 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

Recent available records contain 4 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2EXEL · Nasdaq

Exelixis

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1994San Francisco, California$12.54B market cap
View full Companies Radar profile
58Moderate
Snapshot price$50.61as of page date
Monthly-close return+164.0%five-year window
FY2025 revenue$2.32BEXELIXIS, INC.
Net margin33.7%FY2025
P/E snapshot15.8xone ratio, not a verdict
Prism attention1.9%share across these five
Filing track recordRevenue, USD billions
+61.7%
$0$0.8B$1.5B$2.3BFY2021: $1.435BFY2022: $1.611BFY2023: $1.830BFY2024: $2.169BFY2025: $2.320B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.8%
52-week position71% through range
$33.76$57.57
News mentions2.3K
Community mentions0partial coverage
U.S.-scope patents2645
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal82/100
Management stability90/100
Market position15/100
Capital-event signal80/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 7 M&A involvements, 2 asset-acquisition events and 11 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3NBIX · Nasdaq

Neurocrine

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1992San Diego, California$15.33B market cap
View full Companies Radar profile
57Moderate
Snapshot price$150.8as of page date
Monthly-close return+58.4%five-year window
FY2025 revenue$2.86BNEUROCRINE BIOSCIENCES INC
Net margin16.7%FY2025
P/E snapshot22.9xone ratio, not a verdict
Prism attention2.1%share across these five
Filing track recordRevenue, USD billions
+152.4%
$0$1.0B$1.9B$2.9BFY2021: $1.133BFY2022: $1.489BFY2023: $1.887BFY2024: $2.355BFY2025: $2.861B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 26.0%
52-week position45% through range
$122.1$186.1
News mentions2.6K
Community mentions0partial coverage
U.S.-scope patents1228
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal79/100
Management stability90/100
Market position8/100
Capital-event signal70/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 6 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4AMGN · Nasdaq

Amgen

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1980WILMINGTON$225.51B market cap
View full Companies Radar profile
54Moderate
Snapshot price$417.8as of page date
Monthly-close return+85.3%five-year window
FY2025 revenue$36.75BAMGEN INC
Net margin21.0%FY2025
P/E snapshot25.8xone ratio, not a verdict
Prism attention37.3%share across these five
Filing track recordRevenue, USD billions
+41.5%
$0$12.3B$24.5B$36.8BFY2021: $25.979BFY2022: $26.323BFY2023: $28.190BFY2024: $33.424BFY2025: $36.751B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.1%
52-week position97% through range
$269.8$421.8
News mentions45.2K
Community mentions2.2Kpartial coverage
U.S.-scope patents21491
Prism Insights

What sits behind the readiness signal

Observed risk 9/100higher means more observed risk
Earnings signal70/100
Management stability90/100
Market position52/100
Capital-event signal50/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 70 M&A involvements, 15 asset-acquisition events and 15 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 2 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5BIIB · Nasdaq

Biogen

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2018Cambridge, Massachusetts$31.12B market cap
View full Companies Radar profile
43Cautious
Snapshot price$210.7as of page date
Monthly-close return-37.8%five-year window
FY2025 revenue$9.89BBIOGEN INC.
Net margin13.1%FY2025
P/E snapshot37.0xone ratio, not a verdict
Prism attention24.4%share across these five
Filing track recordRevenue, USD billions
-9.9%
$0$3.7B$7.3B$11.0BFY2021: $10.982BFY2022: $10.173BFY2023: $9.836BFY2024: $9.676BFY2025: $9.891B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -2.6%
52-week position90% through range
$131.5$219.7
News mentions29.6K
Community mentions4.1Kpartial coverage
U.S.-scope patents7929
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal64/100
Management stability90/100
Market position20/100
Capital-event signal5/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 15 M&A involvements, 4 asset-acquisition events and 8 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Exelixis
+164.0%
Gilead
+89.8%
Amgen
+85.3%
Neurocrine
+58.4%
Biogen
-37.8%

Latest revenue

USD billions, official filing scope shown on each company card.

Amgen
$36.75B
Gilead
$29.44B
Biogen
$9.89B
Neurocrine
$2.86B
Exelixis
$2.32B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Exelixis
33.7%
Gilead
28.9%
Amgen
21.0%
Neurocrine
16.7%
Biogen
13.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Amgen
37.3%
Gilead
34.3%
Biogen
24.4%
Neurocrine
2.1%
Exelixis
1.9%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Amgen leads the conversation

It holds 37.3% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $36.75B.

Price path

Exelixis leads the available price paths

Its monthly-close return is +164.0% for the five-year window. At the other end, Biogen is -37.8% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Exelixis has the widest latest margin

Its FY2025 net margin is 33.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Gilead shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 14.0x while its five-year window price return is +89.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · GILD

Gilead

41,601available Prism news records

Prism top themes

Legal, arbitration & regulatory
252
Capital allocation & transactions
235
Price action & investor response
215
Earnings & financial performance
173
Leadership & governance
150

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+16.1%5,432 latest 12m vs 4,680 prior 12m
2024-01: 325 mentions2024-02: 323 mentions2024-03: 326 mentions2024-04: 224 mentions2024-05: 308 mentions2024-06: 285 mentions2024-07: 269 mentions2024-08: 282 mentions2024-09: 215 mentions2024-10: 254 mentions2024-11: 277 mentions2024-12: 277 mentions2025-01: 290 mentions2025-02: 1,061 mentions2025-03: 336 mentions2025-04: 656 mentions2025-05: 510 mentions2025-06: 253 mentions2025-07: 350 mentions2025-08: 388 mentions2025-09: 270 mentions2025-10: 254 mentions2025-11: 295 mentions2025-12: 512 mentions2026-01: 362 mentions2026-02: 475 mentions2026-03: 470 mentions2026-04: 1,153 mentions2026-05: 493 mentions2026-06: 410 mentions2024-012026-06

Machine-classified coverage tone

82.2% positive+4.7 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

conceptual rock albums 159genre-defying rock 159narrative-driven rock 158technical rock journeys 158symphonic rock pieces 158avant-garde rock 158psychedelic textures 158unconventional rock instruments 158

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-13 · trend and themes shown through 2026-06
Areas of research · EXEL

Exelixis

2,343available Prism news records

Prism top themes

Price action & investor response
100
Earnings & financial performance
70
Capital allocation & transactions
25
Legal, arbitration & regulatory
19
Leadership & governance
12

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-40.9%272 latest 12m vs 460 prior 12m
2024-01: 33 mentions2024-02: 16 mentions2024-03: 29 mentions2024-04: 7 mentions2024-05: 22 mentions2024-06: 10 mentions2024-07: 11 mentions2024-08: 12 mentions2024-09: 17 mentions2024-10: 33 mentions2024-11: 10 mentions2024-12: 11 mentions2025-01: 33 mentions2025-02: 209 mentions2025-03: 38 mentions2025-04: 22 mentions2025-05: 19 mentions2025-06: 45 mentions2025-07: 16 mentions2025-08: 22 mentions2025-09: 23 mentions2025-10: 25 mentions2025-11: 4 mentions2025-12: 12 mentions2026-01: 41 mentions2026-02: 49 mentions2026-03: 14 mentions2026-04: 18 mentions2026-05: 41 mentions2026-06: 7 mentions2024-012026-06

Machine-classified coverage tone

93.8% positive+0.4 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 54stock price 26angiogenesis inhibitors 24cancer biomarkers 14stock surge 13earnings report 13share price 12annual earnings 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-12 · trend and themes shown through 2026-06
Areas of research · NBIX

Neurocrine

2,583available Prism news records

Prism top themes

Price action & investor response
110
Capital allocation & transactions
91
Earnings & financial performance
39
Legal, arbitration & regulatory
37
Leadership & governance
24

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-28.7%475 latest 12m vs 666 prior 12m
2024-01: 16 mentions2024-02: 33 mentions2024-03: 16 mentions2024-04: 34 mentions2024-05: 59 mentions2024-06: 16 mentions2024-07: 17 mentions2024-08: 53 mentions2024-09: 26 mentions2024-10: 15 mentions2024-11: 20 mentions2024-12: 18 mentions2025-01: 43 mentions2025-02: 316 mentions2025-03: 39 mentions2025-04: 31 mentions2025-05: 65 mentions2025-06: 23 mentions2025-07: 15 mentions2025-08: 10 mentions2025-09: 13 mentions2025-10: 22 mentions2025-11: 21 mentions2025-12: 19 mentions2026-01: 55 mentions2026-02: 44 mentions2026-03: 22 mentions2026-04: 192 mentions2026-05: 52 mentions2026-06: 10 mentions2024-012026-06

Machine-classified coverage tone

92.7% positive+5.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

ssri effectiveness trials 45treatment-resistant depression studies 31gene therapy rare diseases 31antipsychotic metabolic effects 30antidepressant response rates 26depression treatment outcomes 21stock price 21psychotropic adverse reactions 19

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-04–2026-06-11 · trend and themes shown through 2026-06
Areas of research · AMGN

Amgen

45,238available Prism news records

Prism top themes

Price action & investor response
891
Macro demand & rates
839
Earnings & financial performance
523
Capital allocation & transactions
415
Legal, arbitration & regulatory
415

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-22.2%5,308 latest 12m vs 6,823 prior 12m
2024-01: 418 mentions2024-02: 374 mentions2024-03: 368 mentions2024-04: 298 mentions2024-05: 633 mentions2024-06: 250 mentions2024-07: 251 mentions2024-08: 362 mentions2024-09: 310 mentions2024-10: 296 mentions2024-11: 416 mentions2024-12: 289 mentions2025-01: 347 mentions2025-02: 3,145 mentions2025-03: 437 mentions2025-04: 336 mentions2025-05: 358 mentions2025-06: 276 mentions2025-07: 304 mentions2025-08: 372 mentions2025-09: 518 mentions2025-10: 350 mentions2025-11: 422 mentions2025-12: 481 mentions2026-01: 472 mentions2026-02: 718 mentions2026-03: 369 mentions2026-04: 630 mentions2026-05: 493 mentions2026-06: 179 mentions2024-012026-06

Machine-classified coverage tone

82.7% positive-0.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

generic drug approval 406biosimilar approval 282stock performance 239biosimilar efficacy 234biosimilar market entry 227regulatory pathway biosimilars 182angiogenesis inhibitors 161orphan drug pricing 130

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-15 · trend and themes shown through 2026-06
Areas of research · BIIB

Biogen

29,575available Prism news records

Prism top themes

Price action & investor response
398
Legal, arbitration & regulatory
314
Earnings & financial performance
297
Capital allocation & transactions
255
Leadership & governance
216

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-32.4%3,023 latest 12m vs 4,474 prior 12m
2024-01: 257 mentions2024-02: 323 mentions2024-03: 253 mentions2024-04: 193 mentions2024-05: 313 mentions2024-06: 286 mentions2024-07: 348 mentions2024-08: 202 mentions2024-09: 178 mentions2024-10: 269 mentions2024-11: 212 mentions2024-12: 133 mentions2025-01: 268 mentions2025-02: 2,165 mentions2025-03: 205 mentions2025-04: 185 mentions2025-05: 142 mentions2025-06: 167 mentions2025-07: 223 mentions2025-08: 240 mentions2025-09: 292 mentions2025-10: 234 mentions2025-11: 244 mentions2025-12: 233 mentions2026-01: 249 mentions2026-02: 333 mentions2026-03: 279 mentions2026-04: 382 mentions2026-05: 248 mentions2026-06: 66 mentions2024-012026-06

Machine-classified coverage tone

85.8% positive+1.3 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 239orphan drug pricing 171biosimilar approval 166biosimilar market entry 137biosimilar efficacy 130orphan drug incentives 115regulatory pathway biosimilars 107stock performance 104

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-05–2026-06-12 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

GILD

Gilead

8,101 mentions
Stock and valuation
3,626
Products, pricing and logistics
2,029
Workplace and hiring
183
Other company context
20

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 8,101 records remained after filtering.

AMGN

Amgen

2,234 mentions
Stock and valuation
696
Products, pricing and logistics
516
Workplace and hiring
240
Other company context
4

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 2,234 records remained after filtering.

BIIB

Biogen

4,056 mentions
Products, pricing and logistics
1,542
Stock and valuation
1,110
Workplace and hiring
92
Other company context
8

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 4,056 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

GILD

Gilead

through 2026-04-28
Earnings releases 58M&A 36Leadership changes 14Listing / IPO 9Company announcements 8
  1. M&A

    Gilead completed its acquisition of Arcellx through the merger of Purchaser with and into Arcellx, and without a meeting of the stockholders of Arcellx in accordance with Section 251(h) of the DGCL, with Arcellx surviving such Merger as a wholly owned subsidiary of Gilead.

  2. Asset acquisitions

    Gilead Sciences, Inc. today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.

  3. Lawsuits

    Halper Sadeh LLC is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Arcellx, Inc. (NASDAQ: ACLX )'s sale to Gilead Sciences, Inc. for $115.00 per share in cash plus one contingent value right of $5.00 per share upon the achievement of certain milestones.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EXEL

Exelixis

through 2026-01-11
Earnings releases 19Listing / IPO 11Leadership changes 9M&A 7Board updates 4
  1. Earnings releases

    Total revenues ~ $2.32 0 billion

  2. Listing / IPO

    By Mary Welch The shaky market did just fine by Exelixis Inc., as the company raised $118 million in its initial public offering by selling 9.1 million shares at $13 each.

  3. Business contracts

    Exelixis Inc. (EXEL) Merck & Co. Inc. Collaboration for the joint design and generation of small‑molecule compound libraries for high‑throughput drug screening The companies will jointly ... (5/1)

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NBIX

Neurocrine

through 2026-04-12
Earnings releases 50Leadership changes 7Company announcements 6Business contracts 3Listing / IPO 3
  1. M&A

    Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has agreed to acquire Soleno Therapeutics, Inc. (NASDAQ: SLNO) for $53.00 per share in cash, valuing the target at about $2.9 billion.

  2. Company announcements

    Gano said Ingrezza, now in its eighth year of commercialization, produced $2.51 billion in 2025 revenue, up about 9% year over year, with “double‑digit volume growth” and record new prescriptions (NRX) across multiple quarters.

  3. Leadership changes

    SAN DIEGO , March 17, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

AMGN

Amgen

through 2026-04-29
Earnings releases 42Lawsuits 23Regulatory 17Company announcements 14Leadership changes 8
  1. Regulatory

    First up, the agency has requested—again—that Amgen remove the autoimmune therapy Tavneos from the market. Specifically, the FDA says that unblinded study personnel manipulated results of the pivotal clinical trial that supported the drug’s approval to make it look more effective.

  2. Earnings releases

    Amgen delivered strong performance in 2025, with double‑digit growth in revenues and earnings per share.

  3. Leadership changes

    Katie Casey was promoted to director of corporate affairs for obesity and related conditions communications at Amgen.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BIIB

Biogen

through 2025-02-14
Earnings releases 14M&A 6Asset acquisitions 3Lawsuits 3Business contracts 2
  1. Lawsuits

    Idec filed two separate lawsuits in a California federal court for declaratory judgment for patent non-infringement and invalidity - one against Corixa, Coulter and the University of Michigan at Ann Arbor on six patents for products and processes related to radioimmunotherapy, and the other against GSK on two patents relating to cell-culture media.

  2. Asset acquisitions

    Genentech Inc. is buying Biogen Idec Inc.'s 60-acre biologics manufacturing plant in Oceanside, Calif. - the one that had been slated to make ill-fated Tysabri - for $408 million

  3. M&A

    Biogen Idec on Wednesday said it was acquiring Fumapharm AG, of Lucerne, Switzerland, making it the company's second acquisition in May - the first being Conforma Therapeutics Corp. for $150 million, plus another $100 million hinged on milestones.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence
2020 extracted base$194.20B–$477.15B
2033 extracted forecast$685.30B–$1.37T
Implied source CAGR8.5%
high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

23,986available Prism news records
Latest 12m volume+8.0%10243 vs 9480 records
Positive classified tone40.9%+4.5 pp vs prior four quarters
2024-01: 864 mentions2024-02: 785 mentions2024-03: 800 mentions2024-04: 767 mentions2024-05: 1,047 mentions2024-06: 730 mentions2024-07: 531 mentions2024-08: 845 mentions2024-09: 607 mentions2024-10: 744 mentions2024-11: 594 mentions2024-12: 635 mentions2025-01: 681 mentions2025-02: 1,045 mentions2025-03: 1,331 mentions2025-04: 963 mentions2025-05: 774 mentions2025-06: 564 mentions2025-07: 947 mentions2025-08: 3,046 mentions2025-09: 725 mentions2025-10: 659 mentions2025-11: 609 mentions2025-12: 631 mentions2026-01: 286 mentions2026-02: 1,004 mentions2026-03: 566 mentions2026-04: 1,145 mentions2026-05: 61 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies
3,860
opioid addiction and treatment
3,535
substance abuse education
3,466
controlled substance regulations
3,379
overdose prevention techniques
3,363
substance abuse overdose fatalities
3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

opioid diversion abuse 1,645fentanyl treatment programs 1,608drug overdose 1,576mind-altering drug consumption 1,510cannabis policy reform discussions 1,276medication-assisted treatment opioids 1,223cannabis reclassification 1,150psychedelic mental health studies 1,129

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

harm reduction strategies

3,860 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

1,977 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

Biosimilars entering the market

1,500 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+8.0% news volume

The latest 12 months contain 10,243 matched records versus 9,480 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

40.9% positive · +4.5pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five currently eligible U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances). The builder rechecks price, filing and Prism evidence before assembling the basket. This is a focused research comparison, not a complete sector index.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 13 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Amgen has the widest attention-readiness rank gap

It ranks #1 by measured news attention (37.3%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Amgen in Companies Radar

Exelixis shows a price-operating divergence to inspect

Its displayed filing-revenue change is +61.7% while its available monthly-close return is +164.0%. This is the basket's largest numerical spread; the measures use different units and windows and are not directly equivalent.

Open Exelixis in Companies Radar
Explanations

Attention measures coverage volume, not quality

Amgen's 37.3% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Amgen in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Gilead's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 65/100 score.

Open Gilead in Companies Radar

Stress-test the largest divergence before forming a view

Compare Exelixis's profile with Exelixis's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Exelixis in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon